Xcout IntelGenmab competitors & alternatives
The 12 closest competitors and alternatives to Genmab among biotech companies — ranked by similarity to what Genmab actually does, not by market-cap band.
Subscribe to see Genmab’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Genmab
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
Genmab at a glance
Genmab is a biotech company headquartered in Copenhagen, Denmark. It is publicly listed (GMAB) with a market capitalisation of $23.2B. Xcout tracks 10 named people at Genmab, including Anthony Pagano (Executive Vice President & Chief Financial Officer).
Genmab leadership
- Anthony PaganoExecutive Vice President & Chief Financial Officer
- Rayne WallerExecutive Vice President & Chief Technical Operations Officer
- Gregory David Emil MuellerExecutive VP, General Counsel & Chief Legal Officer
- Judith V. KlimovskyExecutive Vice President & Chief Development Officer
- Tahamtan AhmadiExecutive Vice President, Chief Medical Officer & Head of Experimental Medicines
- Martine J. van VugtExecutive Vice President & Chief Strategy Officer
4 more named people on record for Genmab, with roles, board committees and tenure — see the full roster →
Top 12 Genmab competitors
Ranked by semantic similarity — how close each company is to Genmab by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Merus N.V. is a clinical-stage oncology company that discovers and develops antibody treatments for cancer using its proprietary Multiclonics platform. The company serves patients with cancer by advancing innovative therapeutic pipelines. Merus operates as part of Genmab.
Biotechnology
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.
Similar biotech company
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Similar biotech company
Hansa Biopharma AB (publ) is a biopharmaceutical firm specializing in the creation of immunomodulatory treatments. Leveraging its unique enzyme technology platform, the company aims to facilitate organ transplants and tackle rare autoimmune conditions driven by immunoglobulin G (IgG), alongside developing solutions for gene therapy and cancer. Its flagship therapeutic candidate, Imlifidase, is an enzyme-based therapy designed to break down antibodies. This compound is currently undergoing Phase 3 clinical trials for use in patients receiving sensitized kidney transplants and those suffering from anti-GBM antibody disease. Additionally, Imlifidase is in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. The company's development pipeline also includes NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing), intended for repeated administration in autoimmune disorders, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement), a cancer immunotherapy. Furthermore, Hansa Biopharma has established a preclinical research collaboration with argenx BV to evaluate the combined therapeutic potential of their respective IgG-modulating technologies. Established in 2007, the company's base of operations is located in Lund, Sweden.
Similar biotech company
Numab Therapeutics is a Swiss biotechnology company developing multispecific antibody-based medicines that modulate immune-cell interactions. Its programs target serious diseases including cancer and immune-mediated or inflammatory disorders, serving patients through development and potential partnerships with pharmaceutical companies.
Similar biotech company
Affimed N.V. is a clinical-stage biopharmaceutical company focused on the discovery and development of cancer immunotherapies, with operations spanning the United States, Germany, and the rest of Europe. The company's primary investigational therapy, AFM13, has successfully completed a Phase II clinical study for peripheral T-cell lymphoma. This same candidate is also currently undergoing Phase IIa clinical trials for CD30-positive lymphoma and is in Phase I trials for Hodgkin lymphoma. Beyond its lead product, Affimed is advancing several other promising pipeline compounds. AFM24, a tetravalent, bispecific innate cell engager designed to target both epidermal growth factor receptors and CD16A, is presently in Phase IIa clinical trials for the treatment of various advanced cancers. Additionally, two other innate cell engagers (ICEs) are in preclinical development: AFM28, which is being investigated for acute myeloid leukemia, and AFM32, a candidate focused on the treatment of solid tumors. Affimed N.V. has formed strategic partnerships with esteemed institutions and companies, including The University of Texas MD Anderson Cancer Center, Genentech, Inc., and Roivant Sciences Ltd. The company also receives research funding through an agreement with The Leukemia & Lymphoma Society. Founded in 2000, Affimed N.V. was initially known as Affimed Therapeutics B.V. before officially changing its name in October 2014. Its corporate headquarters are located in Heidelberg, Germany.
Similar biotech company
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Similar biotech company
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
Biotechnology
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
Similar biotech company
Argenx NV is a global immunology company that researches, develops, and commercializes antibody-based therapies for patients suffering from severe autoimmune diseases. The company's proprietary product portfolio includes treatments such as VYVGART and VYVGART Hytrulo, which are designed to target and address pathogenic antibodies.
Similar biotech company
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Genmab and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Genmaband every competitor above — in one live dashboard.
Subscribe to Xcout Intel →